CR20170142A - Composiciones farmacéuticas resistentes al abuso - Google Patents

Composiciones farmacéuticas resistentes al abuso

Info

Publication number
CR20170142A
CR20170142A CR20170142A CR20170142A CR20170142A CR 20170142 A CR20170142 A CR 20170142A CR 20170142 A CR20170142 A CR 20170142A CR 20170142 A CR20170142 A CR 20170142A CR 20170142 A CR20170142 A CR 20170142A
Authority
CR
Costa Rica
Prior art keywords
population
microspheres
active ingredient
gelling agent
abuse
Prior art date
Application number
CR20170142A
Other languages
English (en)
Inventor
Gurvinder Singh Rekhi
Richard Sidwell
Original Assignee
Recro Gainesville Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54063391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170142(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Gainesville Llc filed Critical Recro Gainesville Llc
Publication of CR20170142A publication Critical patent/CR20170142A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención hace referencia a una composición que comprende ingredientes farmacéuticos activos susceptibles o con potencial para el abuso. La invención brinda una composición farmacéutica oral que comprende una primera población de microesferas y una segunda población de microesferas. La primera población de microesferas comprende un ingrediente farmacéuticamente activo susceptible o con potencial para el abuso. La segunda población de microesferas comprende un agente gelificador y un recubrimiento que rodea sustancialmente el agente gelificador, pero que no contiene ingrediente farmacéuticamente activo. La primera población de microesferas y la segunda población de microesferas se pueden separar físicamente, pero son visualmente indistinguibles para el ojo desnudo. Tras el ingreso de agua en la segunda población de microesferas, se provoca la expansión del agente gelificador, lo que genera una masa viscosa que inhibe o evita la extracción del ingrediente activo.
CR20170142A 2014-09-12 2015-09-11 Composiciones farmacéuticas resistentes al abuso CR20170142A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/484,761 US9132096B1 (en) 2014-09-12 2014-09-12 Abuse resistant pharmaceutical compositions
PCT/IB2015/056993 WO2016038584A1 (en) 2014-09-12 2015-09-11 Abuse resistant pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CR20170142A true CR20170142A (es) 2017-08-22

Family

ID=54063391

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170142A CR20170142A (es) 2014-09-12 2015-09-11 Composiciones farmacéuticas resistentes al abuso

Country Status (23)

Country Link
US (6) US9132096B1 (es)
EP (1) EP3191085B1 (es)
JP (2) JP6687624B2 (es)
CN (2) CN107106503B (es)
AU (2) AU2015313785B2 (es)
CA (1) CA2870380C (es)
CR (1) CR20170142A (es)
CY (1) CY1124757T1 (es)
DK (1) DK3191085T3 (es)
ES (1) ES2877058T3 (es)
HR (1) HRP20210973T1 (es)
HU (1) HUE054778T2 (es)
IL (1) IL251011B (es)
LT (1) LT3191085T (es)
MX (1) MX2017003082A (es)
NZ (1) NZ730882A (es)
PL (1) PL3191085T3 (es)
PT (1) PT3191085T (es)
RS (1) RS62056B1 (es)
RU (1) RU2764569C2 (es)
SG (1) SG11201701845XA (es)
SI (1) SI3191085T1 (es)
WO (1) WO2016038584A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CA3074694A1 (en) * 2017-10-02 2019-04-11 Purdue Pharma L.P. Pharmaceutical compositions comprising delayed release gelling agent compositions
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
CN114105875B (zh) * 2021-12-06 2023-11-03 四川大学 一种吗啡衍生物二氢埃托啡的合成方法

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4684516A (en) 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
US5132142A (en) 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
US5654009A (en) 1991-03-25 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Delayed action preparation
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5958459A (en) 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US6077533A (en) 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US7060293B1 (en) 1994-05-25 2006-06-13 Purdue Pharma Powder-layered oral dosage forms
US5411745A (en) 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
DK0914097T3 (da) 1996-03-12 2002-04-29 Alza Corp Sammensætning og doseringsform omfattende opioid antagonist
ES2325046T3 (es) 1996-06-26 2009-08-24 The Board Of Regents, The University Of Texas System Formulacion farmaceutica extruible por fusion en caliente.
US6709678B2 (en) 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
GB9721746D0 (en) 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
US6066339A (en) 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
IL142896A0 (en) 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
RU2230556C2 (ru) 1999-10-29 2004-06-20 Эро-Селтик, С.А. Препаративные формы гидрокодона с контролируемым высвобождением
IT1315274B1 (it) 1999-12-29 2003-02-03 Cip Ninety Two 92 Sa Composizioni farmaceutiche per la somministrazione localizzata nelcavo orale di farmaci antiinfiammatori non stereoidei utili per la
BR0108379A (pt) 2000-02-08 2002-11-05 Euro Celtique Sa Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
CA2431205C (en) 2000-12-05 2005-08-23 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
CA2778114A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
US20030064122A1 (en) 2001-05-23 2003-04-03 Endo Pharmaceuticals, Inc. Abuse resistant pharmaceutical composition containing capsaicin
US7968119B2 (en) 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US7157103B2 (en) 2001-08-06 2007-01-02 Euro-Celtique S.A. Pharmaceutical formulation containing irritant
HUP0401191A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US7144587B2 (en) 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
DE60327807D1 (de) 2002-03-26 2009-07-09 Euro Celtique Sa Gelbeschichtete zusammensetzungen mit verzögerter freisetzung
US7300670B2 (en) 2002-04-03 2007-11-27 Unilab Pharmatech, Ltd. Oral suspension formulation
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7399488B2 (en) 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20040091528A1 (en) 2002-11-12 2004-05-13 Yamanouchi Pharma Technologies, Inc. Soluble drug extended release system
WO2004050066A1 (en) 2002-11-27 2004-06-17 The University Of Georgia Research Foundation, Inc. Microspheres and related processes and pharmaceutical compositions
EP2301526B1 (en) 2003-03-26 2016-03-23 Egalet Ltd. Morphine controlled release system
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20090304793A1 (en) 2003-09-22 2009-12-10 Alpharma, Inc. Sustained release opioid formulations and methods of use
SI1663229T1 (sl) * 2003-09-25 2010-08-31 Euro Celtique Sa Farmacevtske kombinacije hidrokodona in naltreksona
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
ZA200507017B (en) 2004-02-04 2007-03-28 Foamix Ltd Cosmetic and pharmaceutical foam with solid matter
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20060051298A1 (en) * 2004-09-03 2006-03-09 Groenewoud Pieter J Abuse resistent pharmaceutical dosage and method of making same
FR2878161B1 (fr) 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
CA2610662A1 (en) 2005-05-09 2007-05-18 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
BRPI0615860B8 (pt) 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20070184115A1 (en) * 2005-12-30 2007-08-09 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
EP1993519A4 (en) 2006-03-15 2011-12-21 Acura Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR PREVENTING THE ABUSE OF ORGANIC PRODUCTS MANIPULATED ORAL
WO2007107787A2 (en) 2006-03-20 2007-09-27 Karrar Ahmad Khan Liquid and solid dosage formulations containing date fruit (phoenix dactylifera)
CN101453996B (zh) 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
CA2648280C (en) 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
MX2008016115A (es) 2006-06-23 2009-01-20 Elan Pharma Int Ltd Composiciones que comprenden meloxicam nanoparticulado e hidrocodona de liberacion controlada.
AU2007260821B2 (en) 2006-06-23 2012-06-21 Alkermes Pharma Ireland Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
CA2655596C (en) 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8187636B2 (en) * 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
CA2669094A1 (en) 2006-11-08 2008-05-29 Novavax,Inc. Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2008122993A1 (en) 2007-04-09 2008-10-16 Panacea Biotec Limited Controlled release formulation of coated microparticles
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US8486448B2 (en) 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
EP2262367A4 (en) 2008-03-08 2011-04-20 Theraquest Biosciences Inc PHARMACEUTICAL ORAL COMPOSITIONS OF BUPRENORPHINE AND METHOD FOR THEIR USE
TWI519322B (zh) 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
JP5214312B2 (ja) * 2008-04-16 2013-06-19 ホソカワミクロン株式会社 固形製剤およびその製造方法
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
JP5667575B2 (ja) 2008-12-16 2015-02-12 パラディン ラブス インコーポレーテッド 誤用を防止する放出制御製剤
EP2393487B1 (en) 2009-02-06 2016-11-02 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
AR076540A1 (es) * 2009-05-01 2011-06-22 Eurand Inc Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
MX2012003082A (es) 2009-09-17 2012-04-19 Cadila Healthcare Ltd Composiciones farmaceuticas para reducir la absorcion rapida de la dosis inducida por el alcohol.
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
AU2010339882B2 (en) 2009-12-17 2016-10-27 Cima Labs Inc. Abuse-resistant formulations
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
US20130022646A1 (en) 2010-02-09 2013-01-24 Rudnic Edward M Controlled Release Formulations of Opioids
JP6141583B2 (ja) 2010-02-24 2017-06-07 シマ ラブス インク． 濫用耐性製剤
FR2959130A1 (fr) 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
FR2960775A1 (fr) 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
US8861890B2 (en) 2010-11-24 2014-10-14 Douglas Alan Lefler System and method for assembling and displaying individual images as a continuous image
AU2012219322A1 (en) 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
PL2688556T3 (pl) 2011-03-25 2015-10-30 Purdue Pharma Lp Postaci dawkowania o kontrolowanym uwalnianiu
WO2013003622A1 (en) 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
PE20141638A1 (es) * 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
US9065156B2 (en) 2011-08-08 2015-06-23 Wisconsin Alumni Research Foundation Photovoltaic capacitor for direct solar energy conversion and storage
EP3078370B1 (en) 2011-09-16 2018-11-07 Purdue Pharma L.P. Tamper resistant immediate release formulations
WO2013038267A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20150265536A1 (en) * 2011-12-09 2015-09-24 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
EP2819653B1 (en) 2012-03-02 2017-01-11 Rhodes Pharmaceuticals L.P. Tamper resistant immediate release formulations
US9549899B2 (en) * 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US10322120B2 (en) 2012-07-31 2019-06-18 Persion Pharmaceuticals Llc Treating pain in patients with hepatic impairment
CA2888278A1 (en) 2012-10-15 2014-04-24 Isa Odidi Oral drug delivery formulations
US9132096B1 (en) * 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Also Published As

Publication number Publication date
PT3191085T (pt) 2021-06-22
MX2017003082A (es) 2017-07-24
JP6929407B2 (ja) 2021-09-01
US10092559B2 (en) 2018-10-09
EP3191085A1 (en) 2017-07-19
CY1124757T1 (el) 2022-07-22
US20170319576A1 (en) 2017-11-09
DK3191085T3 (da) 2021-06-28
JP2020114855A (ja) 2020-07-30
BR112017004882A2 (pt) 2018-11-06
RS62056B1 (sr) 2021-07-30
IL251011B (en) 2018-05-31
EP3191085B1 (en) 2021-03-24
CN111632041A (zh) 2020-09-08
AU2015313785A1 (en) 2017-04-27
US10960000B2 (en) 2021-03-30
SI3191085T1 (sl) 2021-08-31
AU2020203841B2 (en) 2021-07-08
CN107106503B (zh) 2020-08-14
US20160279062A1 (en) 2016-09-29
HUE054778T2 (hu) 2021-09-28
US9452163B2 (en) 2016-09-27
US20160074385A1 (en) 2016-03-17
US20160074386A1 (en) 2016-03-17
WO2016038584A1 (en) 2016-03-17
JP6687624B2 (ja) 2020-04-22
PL3191085T3 (pl) 2021-10-25
CA2870380A1 (en) 2016-03-12
US20190167663A1 (en) 2019-06-06
NZ730882A (en) 2023-08-25
CN107106503A (zh) 2017-08-29
RU2017112301A3 (es) 2019-04-17
US9486451B2 (en) 2016-11-08
RU2017112301A (ru) 2018-10-12
LT3191085T (lt) 2021-07-12
US9132096B1 (en) 2015-09-15
JP2017527629A (ja) 2017-09-21
CA2870380C (en) 2022-05-10
AU2020203841A1 (en) 2020-07-02
CN111632041B (zh) 2022-10-04
SG11201701845XA (en) 2017-05-30
IL251011A0 (en) 2017-04-30
US9713611B2 (en) 2017-07-25
HRP20210973T1 (hr) 2021-09-17
AU2015313785B2 (en) 2020-03-19
RU2764569C2 (ru) 2022-01-18
ES2877058T3 (es) 2021-11-16

Similar Documents

Publication Publication Date Title
CR20170142A (es) Composiciones farmacéuticas resistentes al abuso
CO2019008487A2 (es) Compuesto de quinazolina
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
CR20160433A (es) Nuevos compuestos
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
BR112013009255A2 (pt) forma de dosagem oral de dissolução rápida de vacina que usa amido
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
BR112015022946A2 (pt) forma de dosagem de cápsula de gelatina macia farmacêutica com goma guar modificada
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
BR112018007399A2 (pt) composição, método de tratamento, kit de partes e forma de dosagem
PH12016501756A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
AR096223A1 (es) Pastilla de nicotina para administración oral
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
BR112014026879A2 (pt) formulação oral, e, substrato
TR201721824A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren modi̇fi̇ye salim sağlayan kombi̇nasyon
CL2016003273A1 (es) Composiciones antimicrobianas con agentes efervescentes